PuSH - Publication Server of Helmholtz Zentrum München: MALT1 is a targetable driver of epithelial-to-mesenchymal transition in claudin-low, triple-negative breast cancer.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Lee, J.L.* ; Ekambaram, P.* ; Carleton, N.M.* ; Hu, D.* ; Klei, L.R.* ; Cai, Z.* ; Myers, M.I.* ; Hubel, N.E.* ; Covic, L.* ; Agnihotri, S.* ; Krappmann, D. ; Bornancin, F.* ; Lee, A.V.* ; Oesterreich, S.* ; McAllister-Lucas, L.M.* ; Lucas, P.C.*

MALT1 is a targetable driver of epithelial-to-mesenchymal transition in claudin-low, triple-negative breast cancer.

Mol. Cancer Res. 20, 373-386 (2022)

Publ. Version/Full Text

Postprint

DOI

PMC

	Open Access Green

Abstract
Metrics
Extra information

MALT1 is the effector protein of the CARMA/Bcl10/MALT1 (CBM) signalosome, a multiprotein complex that drives pro-inflammatory signaling pathways downstream of a diverse set of receptors. Although CBM activity is best known for its role in immune cells, emerging evidence suggests that it plays a key role in the pathogenesis of solid tumors, where it can be activated by selected G protein-coupled receptors (GPCR). Here, we demonstrated that overexpression of GPCRs implicated in breast cancer pathogenesis, specifically the receptors for Angiotensin II and thrombin (AT1R and PAR1), drove a strong epithelial-to-mesenchymal transition (EMT) program in breast cancer cells that is characteristic of claudin-low, triple-negative breast cancer (TNBC). In concert, MALT1 was activated in these cells and contributed to the dramatic EMT phenotypic changes through regulation of master EMT transcription factors including Snail and ZEB1. Importantly, blocking MALT1 signaling, through either siRNA-mediated depletion of MALT1 protein or pharmacologic inhibition of its activity, was effective at partially reversing the molecular and phenotypic indicators of EMT. Treatment of mice with mepazine, a pharmacologic MALT1 inhibitor, reduced growth of PAR1⁺, MDA-MB-231 xenografts and had an even more dramatic effect in reducing the burden of metastatic disease. These findings highlight MALT1 as an attractive therapeutic target for claudin-low TNBCs harboring overexpression of one or more selected GPCRs. IMPLICATIONS: This study nominates a GPCR/MALT1 signaling axis as a pathway that can be pharmaceutically targeted to abrogate EMT and metastatic progression in TNBC, an aggressive form of breast cancer that currently lacks targeted therapies.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Nf-kappa-b; Metastatic Phenotype; Cell-migration; Tumor-growth; Activation; Expression; Protease; Receptor; Inhibitors; Snail

ISSN (print) / ISBN 1541-7786

e-ISSN 1557-3125

Journal Molecular Cancer Research

Quellenangaben Volume: 20, Issue: 3, Pages: 373-386

Publisher American Association for Cancer Research (AACR)

Publishing Place 615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Research Unit Signaling and Translation (SAT)

Grants NHLBI NIH HHS